Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma. DLBCL harboring Epstein-Barr virus (EBV) positive monoclonal B-cell proliferation in patients older than 50 years without any known immunodeficiency or prior lymphoma is termed EBV positive DLBCL of the elderly[@b1][@b2]. The EBV positive DLBCL of the elderly accounts for 8.7%--11.4% of all DLBCL in Asian countries[@b3][@b4][@b5][@b6], but less than 5% in western nations[@b7][@b8]. Since the introduction of rituximab, R-CHOP has become the standard treatment for CD20 positive DLBCL[@b9][@b10]. The outcome of DLBCL patients is improved with R-CHOP, but the impact on the prognosis of EBV positive DLBCL patients remains controversial[@b5][@b6][@b11][@b12].

Most of studies showed the outcome of elderly patients with EBV positive DLBCL treated with R-CHOP was worse than negative ones[@b4][@b5][@b12][@b13][@b14][@b15][@b16]. While few reports showed the impact of EBV positivity was overcome with R-CHOP especially patients received more than three cycles of therapies[@b7][@b11].

Of note, recent reports demonstrated that EBV positive DLBCL could also affect younger patients (\<50 years), who also showed poor response to traditional immunochemotherapy[@b4][@b16][@b17][@b18][@b19]. Hong *et al.*[@b14] showed the prevalence of EBV positivity in the young group was less frequent (young vs. elderly: 6.7% vs. 9.3%), compared with the elderly group. However, they found the EBV positivity in the young group was not closely associated with unfavorable clinical features which was restricted to the elderly group. In addition, the poor prognostic impact of EBV positivity on overall survival (OS) and progression-free survival (PFS) was not observed in the young group, but in the elderly group alone[@b14].

However, almost all of the previous studies, to our knowledge, analyzed the poor prognostic impact in the elderly or young group alone. None of them compared the clinical characteristics and prognosis between the elderly and young groups. Whether EBV positive DLBCL should be divided into two clinically distinct disease entities is still unknown. In present study, we investigated the clinical features of patients with EBV positive DLBCL and the outcome in different age groups.

Material and methods
====================

Ethics statement
----------------

All patients provided informed consent in accordance with requirements of the Declaration of Helsinki, and the research project was approved by the University and Institutional Review Boards.

Patients
--------

According to the 2008 World Health Organization (WHO) classification, we reviewed the medical records of 250 patients who diagnosed as *de novo* DLBCL at our hospital between July 2006 and December 2014. Patients with unknown EBV status, primary central nervous system lymphoma, post-transplant lymphoproliferative disorders, primary mediastinal B-cell lymphoma, and HIV-positive DLBCL were excluded from the study. All of the patients were treated with rituximab plus chemotherapy or chemotherapy alone.

Epstein-Barr virus-encoded RNA (EBER) *in situ* hybridization
-------------------------------------------------------------

EBER *in situ* hybridization was carried out using a fluorescein-conjugated EBER oligonucleotide probe and the purified IgG fraction of a mouse monoclonal anti-fluorescein antibody. Both 20% and 50% were applied as cut-off values for EBER positive tumour cells to assess the differences in clinical parameters, pathological features and survival differences[@b20].

Immunohistochemistry (IHC)
--------------------------

Antibodies applied in the study, according to the manufacturer's instructions, included CD5 (clone EP2952, Abcam, cut-off: 30%), CD10 (clone 56C6, Dako, cut-off: 30%), CD30 (clone CON6D/B5, Abcam, cut-off: 30%), Ki-67 (clone Mib-1, Dako), Myc (clone Y69, Abcam, cut-off: 40%), Bcl2 (clone 124, Dako, cut-off: 50%), Bcl6 (clone LN22, Dako, cut-off: 30%), MUM1 (clone MUM1p, Dako, cut-off: 30%), FOXP1 (clone JC12, Abcam, cut-off: 60%), GCET1 (clone RAM341; Abcam, cut-off: 60%) and LMO2 (clone 1A9-1, Santa Cruz, cut-off: 30%). The cell of origin (COO) was classified according to Hans, Choi, Tally and Visco-Young algorithms. The specific cut-off of each antibody used in different algorithms was described previously[@b21][@b22][@b23][@b24].

Fluorescence *in situ* hybridization (FISH)
-------------------------------------------

FISH analysis was performed according to the manufacturer's instructions with MYC dual-color, break-apart translocation probe (Vysis LSI) and IGH/BCL2 dual-color, dual-fusion translocation probe (Vysis LSI). The cut-off levels for the probes were established by evaluating the split signal distribution in samples of reactive lymphoid tissues, calculating the mean number of split signals plus three times the standard deviation. The cut-off levels were 14% and 5% for MYC break apart probe and IGH/BCL2 dual-color, dual-fusion translocation probe, respectively.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS software, version 20.0. Chi-square and Fisher exact tests were used to compare categorical variables . OS and PFS were defined according to Cheson 2014[@b25]. Survival curves were plotted by using Kaplan-Meier method and were compared by using log-rank test. For all the tests, a probability value of less than 0.05 (2-sided) was considered statistically significant.

Results
=======

Prevalence of EBV positive DLBCL in the cohort
----------------------------------------------

A total of 250 cases with DLBCL were included in the analysis as the whole cohort. Using 20% as cut-off, 14.0% (35/250) cases showed EBER positivity. The prevalence of EBER positivity were 15.1% (25/166) and 11.9% (10/84) in the elderly and young group, respectively. No significant difference of incidence was observed between the two groups (*P* = 0.497). When a cut-off of 50% was used for EBER positivity, the incidence of EBER positive cases was 10.4% (26/250). Accordingly, 11.4% (19/166) and 8.3% (7/84) were positive for EBER in the elderly and young groups, respectively. No significant difference of prevalence was observed between the two groups (*P* = 0.466).

EBV positivity and clinical features
------------------------------------

In the whole cohort, compared with EBER negative cases, EBER positive (for both cut-off values) patients showed male predominance, advanced clinical stages (stage III/IV), poor performance status (ECOG PS status 2--4) and lower response to first-line treatment. ([Table 1](#t1){ref-type="table"},[2](#t2){ref-type="table"}). Using 20% as cut-off, EBV positivity was significantly associated with male sex (76.0% vs. 53.9%), poor PS status (40% vs. 12.5%) and lower response to first-line treatment (64.0% vs. 84.4%), compared with negative cases. In the young group, EBER positivity was strongly associated with poor PS status (30.0% vs. 5.8%) and lower response to first-line treatment (70.0% vs. 94.6%), With regard to other clinical features, although not statistically significant, EBV positive patients more frequently showed unfavorable characteristics compared with negative cases in both elderly and young groups ([Table 1](#t1){ref-type="table"}). However, no significant differences of these clinical characteristics were observed between different age groups. When we analyzed above parameters with a cut-off value of 50% for EBER, although fewer factors with significant differences were observed, EBV positive cases still showed majority of unfavaorable clinical features compared with negative ones, regardless of ages ([Table 2](#t2){ref-type="table"}).

EBV positivity and clinical prognostic indicators
-------------------------------------------------

In the whole cohort, EBER positivity (for both cut-off values) was significantly associated with elevated serum C reactive protein (CRP) level, β2 microglobulin (β2M) level, CA125 level, erythrocyte sedimentation rate (ESR) and Ferritin level ([Table 3](#t3){ref-type="table"},[4](#t4){ref-type="table"}). Using 20% as cut-off, in the elderly patients, compared with EBER negative cases, EBER positive ones more frequently had elevated serum CRP level (71.4% vs. 45.2%), β2M level (71.4% vs. 45.8%), CA125 level (61.5% vs. 29.3%), ESR (92.9% vs. 22.7%) and Ferritin level (55.6% vs. 29.3%). In the young group, EBER positivity was associated with all of above clinical prognositic factors ([Table 3](#t3){ref-type="table"}). Additionally, no significant differences of these prognostic features were observed between different age groups. When we analyzed those parameters with the 50% for cut-off of EBER, similar results were observed ([Table 4](#t4){ref-type="table"}).

EBV positivity and pathological characteristics
-----------------------------------------------

In the whole cohort, EBER positivity (for both cut-off values) was significantly associated with less frequent Bcl6 expression, more common CD30 expression, higher Ki-67 expression (≥70%) (*P *\< 0.001), and higher incidence of double hit lymphoma (DHL) ([Table 5](#t5){ref-type="table"},[6](#t6){ref-type="table"}). Using 20% as cut-off, EBER positivity was associated with less frequent Bcl2 (40.0% vs. 62.1%), Bcl6 (28% vs. 65%) and FOXP1 expression (45.5% vs. 68.5%), more common CD30 (28.0% vs. 6.4%), higher Ki-67 expression (70.8% vs. 34.0%) and Myc expression (60.9% vs. 37.6%), more incidence of double protein expression (DPE) (44.0% vs. 24.8%), MYC gene rearrangement (34.4% vs. 10.7%) and double hit lymphoma (DHL) (13.0% vs. 1.0%). Other factors, including: lower CD10 expression (16.0% vs. 24.8%) and more common of non-GCB subtype with Choi (72.7% vs. 57.9%) and Visco-Young (75.0% vs. 59.3%) algorithms although not statistically significant, were shared by EBV positive patients, compared with negative cases ([Table 5](#t5){ref-type="table"}). In the young group, EBER positivity was associated with lower CD10 (0% vs. 28.0%) and LMO2 expression (60.0% vs. 86.1%), more common with CD30 expression (30.0% vs. 6.8%), MYC gene rearrangement (33.3% vs. 10.8%) and BCL2/IGH translocation (33.3% vs. 8.1%) ([Table 5](#t5){ref-type="table"}). In addition, no significantly differences were recognized among all of the pathological features between different age groups. When we analyzed those parameters with the cut-off value of 50%, similar results were observed in both age groups ([Table 6](#t6){ref-type="table"}).

Survival analysis
-----------------

### Prognosis of EBV status

In the whole cohort, after a median follow-up of 29.3 (range, 1.3--122.4) months, patients with EBV positive DLBCL showed significantly worse OS (median OS: 20% as EBER cut-off: 18.3 months vs. not reached, *P *\< 0.0001; 50% as EBER cut-off: 37.0 months vs. not reached, *P* = 0.0021) ([Fig. 1a,c](#f1){ref-type="fig"}) and PFS (median PFS: 20% as EBER cut-off: 11.9 months vs. not reached, *P *\< 0.0001; 50% as EBER cut-off: 20.5 months vs. not reached, *P *\< 0.0001) ([Fig. 1b,d](#f1){ref-type="fig"}) than EBV negative ones.

### Prognosis of EBV status in the elderly group

We carried out survival analysis in the elderly group. Patients with EBV positive DLBCL showed significantly worse OS (median OS: 20% as EBER cut-off: 17.0 months vs. not reached, *P* \< 0.0001; 50% as EBER cut-off: 37.0 months vs. not reached, *P* = 0.0337) ([Fig. 2a,c](#f2){ref-type="fig"}) and PFS (median PFS: 20% as EBER cut-off: 9.8 months vs. not reached, *P* \< 0.0001; 50% as EBER cut-off: 20.7 months vs. not reached, *P *\< 0.0001) ([Fig. 2b,d](#f2){ref-type="fig"}) compared with those with EBV negative DLBCL.

### Prognosis of EBV status in the young group

We carried out survival analysis in the young group. Patients with EBV positive DLBCL showed significantly worse OS (median OS: 20% as EBER cut-off: 32.2 months vs. not reached, *P* \< 0.0001; 50% as EBER cut-off: 36.5 months vs. not reached, *P *= 0.0255) ([Fig. 3a,c](#f3){ref-type="fig"}) and PFS (median PFS: 20% as EBER cut-off: 16.5 months vs. not reached, *P *\< 0.0001; 50% as EBER cut-off: 20.5 months vs. not reached, *P *= 0.0010) ([Fig. 3c,d](#f3){ref-type="fig"}) than patients with EBV negative DLBCL.

### Prognosis of EBV positivity between different age groups

We further compared the survival difference between the elderly and young group. Unexpectedly, elderly patients with EBV positive DLBCL of the elderly group showed OS (median OS: 20% as EBER cut-off: 17.0 vs. 32.2 months, *P* = 0.8434; 50% as EBER cut-off: 37.0 vs. 36.5 months, *P* = 0.8058) ([Fig. 4a,c](#f4){ref-type="fig"}) and PFS (median PFS: 20% as EBER cut-off: 9.8 vs. 16.3 months, *P* = 0.5878; 50% as EBER cut-off: 20.7 vs. 20.5 months, *P* = 0.8323) similar to those of their young counterparts ([Fig. 4b,d](#f4){ref-type="fig"}). In addition, we also analyzed the survival differences with other age cut-offs (40 or 60 years old), however, no difference of OS or PFS was recognized between different age groups with EBV positive DLBCL (data not shown).

Discussion
==========

While using 20% and 50% as cut-off vaues, the incidences of EBV positive DLBCL were 14.0% (35/250) and 10.4% (26/250), respectively. Our result was similar to that of a previous study in Peru (14.9% for 20% cut-off and 9.0% for 50% cut-off)[@b26]. However, taking different cut-off vaues used in previous studies into consideration, the incidence of EBV positive lymphoma appeared to be higher than those reported in previous studies in Asian countries[@b4][@b20].

In current study, EBV positivity, defined by either EBER cut-off (20% or 50%), had a close association with male sex, advanced clinical stage, poor PS status and lower response to first-line treatment, which was observed in both young and elderly patients. These results indicated that EBV positive DLBCL were clinically aggressive, irrespective of age. Based on these, we then analyzed the association between EBV positivity and the clinical prognostic indicators reported previously[@b27][@b28][@b29][@b30][@b31][@b32]. The results showed that EBV positivity had a strong relationship with elevated serum CRP level, β2M level, CA125 level, ESR level and ferritin level, regardless of age and EBER cut-off value.

We subsequently included CD10, Bcl6, MUM1, FOXP1, GCET1 and LMO2 in our study as these markers were used to establish a diagnosis and further classify DLCBL into GCB or non-GCB subtype[@b21][@b22][@b23][@b24]. Research showed the majority of EBV positive DLBCL of the elderly had a non-GCB predominance, which is a subtype with poor prognosis. In our study, we accessed the COO with four conventional IHC algorithms. Although EBV positive DLBCL of the elderly group showed less frequent FOXP1 expression and the young group demonstrated less common of LMO2 expression, the EBV positive DLBCL (both age groups), although not statistically significant, demonstrated the non-GCB subtype preference than negative ones. However, the COO difference was observed in Choi and Visco-Young algorithms alone. The poor concordance among IHC algorithms may be one of reasons to explain our results, since 20--30% cases among the IHC algorithms are discrepant[@b22][@b33]. We also analyzed CD5, Myc, Bcl2, Ki-67 expression and DPE, MYC and BCL2 gene rearrangement and DHL because of their efficacy in prognostication[@b34][@b35][@b36]. We also chose CD30 due its significant association with EBV positivity in DLBCL that was observed in several previous studies[@b7][@b15][@b37]. Moreover, EBER^+^/CD30^+^ DLBCL had significantly poorer outcomes compared with EBER^−^/CD30^+^ cases[@b38]. Using the cut-off values of these proteins applied in above studies[@b7][@b34][@b35][@b36][@b37], we accessed the incidences of these pathological factors in DLBCL according to EBV status and age. Interestingly, EBER positivity was associated with less frequent Bcl6 expression, which was also confirmed by previous studies[@b7]. Moreover, Constitutive expression of EBV-derived miRNAs, including BART3, BART7, BART9 and BART17-5p, was found to be capable of repressing Bcl6 expression, partly accounting for reduced Bcl6 expression in EBV positive lymphoma[@b39]. The proportions of Myc expression, DPE, MYC rearrangement and DHL were much higher in EBV positive DLBCL, which were consistent with the aggressive biological behavior of EBV positive DLBCL[@b1][@b11][@b13]. DPE and DHL were more frequent in EBV positive cases than EBV negative ones, which was inconsistent with the study by Ok *et al.*[@b7], probably due to different ethnic background or geographic variation of EBV strains. Bcl2 expression was less frequent in EBV positive DLBCL. However, this was not observed in a previous study[@b7]. Of note, in that study, cut-off for Bcl2 was 70%, rather than 50%. Higher Ki-67 expression was observed in EBV positive patients, suggesting that EBV infection contributes the aggressiveness of EBV positive DLBCL[@b40]. Similar to previous studies[@b40], the significant association of CD30 with EBV positivity in DLBCL was also confirmed in our study. However, the mechanism underlying this phenomenon remains to be determined. It is possible that CD30 functions synergistically with EBV to transform B lymphocytes[@b41].

In present study, although the treatment for EBV positive DLBCL was more intensive than negative ones (much higher percentage of immunochemotherapy in EBV positive DLBCL), consistent with most studies[@b4][@b12][@b16][@b19], both age groups with EBV positive DLBCL showed significantly worse OS and PFS than negative cases. Further comparison showed that EBV positive DLBCL of the elderly group had similar OS and PFS to the young counterparts. It is worth mentioning that the EBV positive DLBCL patients (both elderly and young) were treated with similar regimens. Actually, EBV positive DLBCL of the elderly was included as a provisional entity in the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues, in which the WHO Working Group considered that there was insufficient evidence to recognize this entity as a distinct disease at that time[@b3][@b42]. EBV positive DLBCL of the young group that had no evidence of underlying immunosuppression had been described in previous reports[@b4][@b16]. The identification of these young cases arised an interrogation that if EBV positive DLBCL might be an entity that was not restricted to patients who were older than 50 years old alone. However, one recent study did not recognized unfavorable baseline characteristics in young patients with EBV positive DLBCL[@b14]. Therefore, they concluded that EBV positive DLBCL of young group should be considered to be a distinct clinical entity different from EBV positive DLBCL of the elderly[@b14]. In present study, to say the least, no distinct difference was recognized in the clinical and pathological features between EBV positive DLBCL in the elderly and the young group, which was in accordance with most studies[@b4][@b12]. These unfavorable factors were shared by both groups, which indicated that EBV positive DLBCL belongs to a unique entity with aggressive clinical features[@b7][@b11][@b13][@b14][@b15][@b20][@b43], regardless of age. Since there is no uniform cut-off for EBV positivity, some reports attributed the inconsistent results to the different cut-off values used in different studies[@b7][@b11][@b13][@b14][@b44][@b45][@b46]. However, by appling two most frequently-used cut-off values, our study indicated that EBER positive patients harbored more unfavorable clinical and pathological features than EBER negative ones, regardless of the cut-off values of EBV.

Several studies had reported that EBV positive patients showed an inferior prognosis compared with EBV negative cases, especially the elderly group[@b7][@b11][@b13][@b15][@b18][@b47][@b48]. The clinical course is often aggressive with a median survival of 2 years and an overall 5-year survival rate of approximately 25%[@b4][@b5][@b8]. In our study, accordantly, EBV positive DLBCL of the elderly showed worse survival than negative counterparts. Many studies also showed the young patients of EBV positivity demonstrated poor outcome with traditional immunochemotherapy[@b4][@b12][@b16][@b19], which was confirmed in current study. However, the study by Hong *et al.* revealed young EBV positive DLBCL patients (6.7%, 13/195) had an outcome similar to EBV negative ones[@b14].

In fact, the biological mechanism underlying similar clinical and pathological features and outcome between these age groups remains to be investigated. To elucidate molecular mechanisms involved EBV positive DLBCL, Ok *et al.*[@b7] evaluated GEP profiles signatures of DLBCL with different EBV status. It is worth noting that in the 24 EBV positive patients included in that study, 7 patients were younger than 50 years old. They revealed the NF-κB activation and JAK/STAT activation were enhanced in EBV positive DLBCL compared with negative counterparts by gene set enrichment analysis. Thus, EBV positive DLBCL might share similar GEP signatures and common pathogenic pathways, irrespective of age. It also has been reported that ABC-like DLBCL more frequently exhibited JAK-STAT and NF-κB pathways activation compared with GCB-like DLBCL[@b49][@b50] Interestingly, Kato *et al.* demonstrated that NF-κB and JAK-STAT pathways were more remarkably activated in EBV positive DLBCL compared with ABC-like EBV negative DLBCL[@b47]. Using miRNA array platforms, Andrade *et al.*[@b43] showed that miR-146b and miR-222 were highly specific for EBV positive DLBCL. The targets of hsa-miR-146b and its viral counterpart are INTS6 and IPO, both of which are tumor suppressors[@b51] and mediators of inflammation[@b26] Similarly, hsa-miR-222 interferes with important proteins related to oncogenesis, cell cycle regulation, cell transcription, cell adhesion, oxidative stress, and apoptosis inhibition[@b52]. Besides, NF-κB pathway can be activated indirectly by hsa-miR-222[@b43]. All of the above findings suggested that EBV positive DLBCL shared a common molecular basis, irrespective of age.

Additionally, using other age cut-off values, we did not recognized any significant differences of survival between elderly and the young patients of EBV positivity. This also indicated that the young group patients should not be excluded from the whole cohort of EBV positive patients and the 50 years old cut-off might not be applicable in the R-CHOP era.

In summary, EBV positive DLBCL patients shared poor prognostic features, regardless of elderly or young group. The survival analysis also showed that EBV DLBCL of the elderly showed a similar outcome to the young ones. Based on these results, we suggest that the age criterion, and possibly the name-EBV positive DLBCL of elderly itself, be modified in future.
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The EBV positive patients of the young group showed significantly worse OS (**a**,**c**) and PFS (**b**,**d**) than negative ones, regardless of the EBER cut-off values. Abbreviations: EBER: Epstein-Barr virus-encoded RNA; EBV: Epstein-Barr virus; OS: overall survival; PFS: progression-free survival.](srep12168-f3){#f3}

![The survival differences of EBV positive DLBCL beween different age groups.\
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###### Patients' characteristics in different groups (EBER cut-off: 20%).

  Variable       Number.(%)   **All patients (N** **=** **250)**   *P* value    **Elderly group**   *P* value   **Young group**   *P* value                         
  ------------- ------------ ------------------------------------ ------------ ------------------- ----------- ----------------- ----------- ---------- ----------- -----------
  Age               250                       35                      215                              25             141                        10         74            
  ≥50y           166 (66.4)               25 (71.4)                141 (65.6)         0.497            25             141            NA          NA         NA          NA
  \<50y          84 (33.6)                10 (28.6)                74 (34.4)                           NA             NA                         10         74            
  Sex               250                       35                      215                              25             141                        10         74            
  Male           144 (57.6)               27 (77.1)                117 (54.4)       **0.012**       19 (76.0)      76 (53.9)      **0.040**   8 (80.0)   41 (55.4)     0.182
  Female         106 (42.4)                8 (22.9)                98 (45.6)                        6 (24.0)       65 (46.1)                  2 (20.0)   33 (45.6)        
  Site              250                       35                      215                              25             141                        10         74            
  Extranodal     106 (41.6)               20 (57.1)                86 (40.0)          0.057         15 (60.0)      62 (44.0)        0.139     5 (50.0)   24 (32.4)     0.303
  Lymph node     144 (58.4)               15 (42.9)                129 (60.0)                       10 (40.0)      79 (56.0)                  5 (50.0)   50 (67.6)        
  Stage             250                       35                      215                              25             141                        10         74            
  I/II           125 (50.0)               12 (34.3)                113 (52.6)       **0.045**       8 (32.0)       68 (48.2)        0.133     4 (40.0)   45 (60.8)     0.307
  III/IV         125 (50.0)               23 (65.7)                102 (47.4)                       17 (68.0)      73 (51.8)                  6 (60.0)   29 (39.2)        
  ECOG PS           238                       25                      213                              15             144                        10         69            
  0--1           207 (83.5)               16 (64.0)                191 (89.7)       **0.002**       9 (60.0)      126 (87.5)      **0.013**   7 (70.0)   65 (94.2)   **0.040**
  2--4           31 (16.5)                 9 (36.0)                22 (10.3)                        6 (40.0)       18 (12.5)                  3 (30.0)    4 (5.8)         
  ESI               242                       30                      212                              20             139                        10         73            
  0--1           194 (80.2)               20 (66.7)                174 (82.1)       **0.048**       13 (65.0)     112 (80.6)        0.143     7 (70.0)   62 (84.9)     0.361
  \>1            48 (19.8)                10 (33.3)                38 (17.9)                        7 (35.0)       27 (19.4)                  3 (30.0)   11 (15.1)        
  IPI               237                       29                      208                              19             139                        10         69            
  0--2           174 (73.4)               17 (58.6)                157 (75.5)         0.054         9 (47.4)       93 (66.9)        0.095     8 (80.0)   64 (92.8)     0.214
  3--5           63 (26.6)                12 (41.4)                51 (24.5)                        10 (52.6)      46 (33.1)                  2 (20.0)    5 (7.2)         
  Treatment         250                       35                      215                              25             141                        10         74            
  R-CHOP         125 (50.0)               27 (77.1)                98 (45.6)           NA           19 (76.0)      58 (41.1)         NA       8 (80.0)   40 (54.1)      NA
  R-DA- EPOCH    35 (14.0)                 7 (20.0)                28 (13.0)           NA           5 (20.0)       23 (16.3)         NA       2 (20.0)    5 (6.8)       NA
  CHOP           90 (36.0)                 1 (2.9)                 89 (41.4)           NA            1 (4.0)       60 (42.6)         NA       0 (0.0)    29 (39.1)      NA
  Response          250                       35                      215                              25             141                        10         74            
  CR(u)/PR       212 (84.8)               23 (65.7)                189 (87.9)       **0.001**       16 (64.0)     119 (84.4)      **0.025**   7 (70.0)   70 (94.6)   **0.034**
  No response    38 (15.2)                12 (34.3)                26 (12.1)                        9 (36.0)       22 (15.6)                  3 (30.0)    4 (5.4)         

Abbreviations: EBV: Epstein-Barr virus; ESI: extranodal sites involvement; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IPI: International Prognostic Index; NCCN: National Comprehensive Cancer Network; Chemo: R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DA-EPOCH: Dose-adjusted EPOCH-R (\[etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin\] + rituximab); CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; chemotherapy; CR(u): complete remission(unconfirmed); PR: partial remission.

###### Patients' characteristics of in different groups (EBER cut-off: 50%).

  Variable       Number.(%)   **All patients (N** **=** **250)**   *P* value    **Elderly group**   *P* value   **Young group**   *P* value                         
  ------------- ------------ ------------------------------------ ------------ ------------------- ----------- ----------------- ----------- ---------- ----------- -------
  Age               250                       26                      224                              19             147                        7          77          
  \>50y          166 (66.4)               19 (73.1)                147 (65.6)                       19 (100)      147 (65.6)         NA          NA         NA        NA
  ≤50y           84 (33.6)                 7 (26.9)                77 (34.4)                           NA             NA                      7 (100)    77 (34.4)      
  Sex               250                       26                      224                              19             147                        7          77          
  Male           144 (57.6)               21 (80.8)                123 (54.9)       **0.012**       15 (78.9)      80 (54.4)      **0.042**   6 (85.7)   43 (55.8)   0.230
  Female         106 (42.4)                5 (19.2)                101 (45.1)                       4 (21.1)       67 (45.6)                  1 (14.3)   34 (44.2)      
  Site              250                       26                      224                              19             147                        7          77          
  Extranodal     106 (41.6)               11 (42.3)                95 (42.4)          0.992         9 (47.4)       68 (46.3)        0.927     2 (28.6)   27 (35.1)   1.000
  Lymph node     144 (58.4)               15 (57.7)                129 (57.6)                       10 (52.6)      79 (53.7)                  5 (71.4)   50 (64.9)      
  Stage             250                       26                      224                              19             147                        7          77          
  I/II           125 (50.0)                6 (23.1)                119 (53.1)       **0.004**       4 (21.1)       72 (49.0)      **0.021**   2 (28.6)   47 (61.0)   0.122
  III/IV         125 (50.0)               20 (76.9)                105 (46.9)                       15 (78.9)      75 (51.0)                  5 (71.4)   30 (39.0)      
  ECOG PS           238                       20                      218                              13             146                        7          72          
  0--1           207 (83.5)               14 (70.0)                193 (88.5)       **0.001**       9 (69.2)      126 (86.3)        0.111     5 (71.4)   67 (93.1)   0.115
  2--4           31 (16.5)                 6 (30.0)                25 (11.5)                        4 (30.8)       20 (13.7)                  2 (28.6)    5 (6.9)       
  ESI               242                       21                      221                              14             145                        7          76          
  0--1           194 (80.2)               16 (76.2)                178 (80.5)         0.577         10 (71.4)     115 (79.3)        0.501     6 (85.7)   63 (82.9)   1.000
  \>1            48 (19.8)                 5 (23.8)                43 (19.5)                        4 (28.6)       30 (20.7)                  1 (14.3)   13 (17.1)      
  IPI               237                       20                      217                              13             145                        7          72          
  0--2           174 (73.4)               11 (55.0)                163 (75.1)         0.051         6 (46.2)       96 (66.2)        0.224     5 (71.4)   67 (93.1)   0.115
  3--5           63 (26.6)                 9 (45.0)                54 (24.9)                        7 (53.8)       49 (33.8)                  2 (28.6)    5 (6.9)       
  Treatment         250                       26                      224                              19             147                        7          77          
  R-CHOP         125 (50.0)               23 (88.5)                102 (45.6)          NA           18 (94.7)      59 (40.1)         NA       5 (71.4)   43 (55.8)    NA
  R-DA- EPOCH    35 (14.0)                 2 (7.6)                 33 (14.7)           NA            0 (0.0)       28 (19.1)         NA       2 (28.6)    5 (6.5)     NA
  CHOP           90 (36.0)                 1 (2.9)                 89 (39.7)           NA            1 (5.3)       60 (40.8)         NA       0 (0.0)    29 (37.7)    NA
  Response          250                       26                      224                              19             147                        7          77          
  CR(u)/PR       212 (84.8)               18 (69.2)                194 (86.6)       **0.037**       13 (68.4)     135 (91.8)      **0.008**   5 (71.4)   73 (94.8)   0.076
  No response    38 (15.2)                 8 (30.8)                30 (13.4)                        6 (31.6)       12 (8.2)                   2 (28.6)    4 (5.2)       

Abbreviations: EBV: Epstein-Barr virus; ESI: extranodal sites involvement; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IPI: International Prognostic Index; NCCN: National Comprehensive Cancer Network; Chemo: R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DA-EPOCH: Dose-adjusted EPOCH-R (\[etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin\] + rituximab); CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; chemotherapy; CR(u): complete remission(unconfirmed); PR: partial remission.

###### Clinical features of patients in different groups (EBER cut-off: 20%).

  Variable    Number.(%)   **All age**   *P* value    **Elderly group**   *P* value   **Young group**    *P* value                           
  ---------- ------------ ------------- ------------ ------------------- ----------- ----------------- ------------- ----------- ----------- -----------
  CRP            117           20            97                              14             62                            6          35            
  Over ULN    57 (48.7)     15 (75.0)    42 (43.3)        **0.010**       10 (71.4)      28 (45.2)         0.076      5 (83.3)    14 (40.0)     0.080
  Normal      60 (51.3)     5 (25.0)     55 (56.7)                        4 (28.6)       34 (54.8)                    1 (16.7)    21 (60.0)        
  β2MG           134           22           109                              14             72                            8          40            
  Over ULN    59 (44.0)       16 ()      43 (72.7)        **0.003**       10 (71.4)      33 (45.8)         0.080      6 (75.0)    10 (25.0)   **0.012**
  Normal      75 (56.0)       6 ()       69 (27.3)                        4 (28.6)       39 (54.2)                    2 (25.0)    30 (75.0)        
  TK1             92           15            77                               9             52                            6          25            
  Over ULN    28 (30.4)     4 (26.7)     24 (31.2)          1.000         2 (22.2)       15 (28.8)         1.000      2 (33.3)    9 (36.0)      1.000
  Normal      64 (69.6)     11 (73.3)    53 (68.8)                        7 (77.8)       37 (71.2)                    4 (66.7)    16 (64.0)        
  CA125          108           18            90                              13             58                            5          32            
  Over ULN    42 (38.9)     13 (72.2)    29 (32.2)        **0.001**       8 (61.5)       17 (29.3)         0.051      5 (100.0)   12 (37.5)   **0.014**
  Normal      66 (61.1)     5 (27.8)     61 (67.8)                        5 (38.5)       41 (70.7)                     0 (0.0)    20 (62.5)        
  ESR            163           22           141                              14             88                            8          53            
  Over ULN    49 (30.1)     19 (86.4)    30 (21.3)       **\<0.001**      13 (92.9)      20 (22.7)      **\<0.001**   6 (75.0)    10 (18.9)   **0.003**
  Normal      114 (69.9)    3 (13.6)     111 (78.7)                        1 (7.1)       68 (77.3)                    2 (25.0)    43 (81.1)        
  Ferritin       152           24           128                              18             82                            6          46            
  Over ULN    52 (34.2)     15 (62.5)    37 (28.9)        **0.001**       10 (55.6)      24 (29.3)       **0.033**    5 (83.3)    13 (28.3)   **0.015**
  Normal      100 (65.8)    9 (37.5)     91 (71.1)                        8 (44.4)       58 (70.7)                    1 (16.7)    33 (71.7)        
  LDH            250           34           216                              24             139                          10          77            
  Over ULN    114 (45.6)    20 (58.8)    94 (43.5)          0.096         15 (62.5)      59 (42.4)         0.068      5 (50.0)    35 (45.5)     1.000
  Normal      136 (54.4)    14 (41.2)    122 (56.5)                       9 (37.5)       80 (57.6)                    5 (50.0)    42 (54.5)        
  CK             149           24           125                              16             70                            8          55            
  Complex      5 (3.4)       1 (4.2)      4 (3.2)           0.590          1 (6.2)        2 (2.9)          0.465       0 (0.0)     2 (3.6)      1.000
  Normal      144 (96.6)    23 (95.8)    121 (96.8)                       15 (93.8)      68 (97.1)                    8 (100.0)   53 (96.4)        
  BM             150           25           125                              17             81                            8          44            
  Positive    17 (11.3)     4 (16.0)     13 (10.4)          0.487         3 (17.6)        8 (9.9)          0.398      1 (12.5)    5 (11.4)      1.000
  Negative    133 (88.7)    21 (84.0)    112 (89.6)                       14 (82.4)      73 (90.1)                    7 (87.5)    39 (88.6)        

Abbreviations: EBV: Epstein-Barr virus; CRP: serum C reactive protein; ULN: upper limit of normal; β2MG: β2 microglobulin; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; CK: chromosome karyotype; BM: bone marrow.

###### Clinical features of patients in different groups (EBER cut-off: 50%).

  **Variable**    **Number.(%)**   **All age**   ***P* value**   **Elderly group**   ***P*** **value**   **Young group**   ***P*** **value**                          
  -------------- ---------------- ------------- --------------- ------------------- ------------------- ----------------- ------------------- ----------- ----------- -----------
  CRP                  117             19             98                                    13                 63                                  6          35            
  Over ULN          57 (48.7)       15 (78.9)      42 (42.9)         **0.004**           10 (76.9)          28 (44.4)          **0.033**       5 (83.3)    14 (66.7)     0.080
  Normal            60 (51.3)       4 (21.1)       56 (57.1)                             3 (23.1)           35 (55.6)                          1 (16.7)    21 (33.3)        
  β2MG                 134             18             116                                   11                 75                                  7          41            
  Over ULN          59 (44.0)       14 (77.8)      45 (38.8)         **0.002**           9 (81.8)           34 (45.3)          **0.024**       5 (71.4)    11 (26.8)   **0.033**
  Normal            75 (56.0)       4 (22.2)       71 (61.2)                             2 (18.2)           41 (54.7)                          2 (28.6)    30 (73.2)        
  TK1                   92             14             78                                     8                 53                                  6          25            
  Over ULN          28 (30.4)       4 (28.6)       24 (30.8)           1.000             2 (25.0)           15 (28.3)            1.000         2 (33.3)    9 (36.0)      1.000
  Normal            64 (69.6)       10 (71.4)      54 (69.2)                             6 (75.0)           38 (71.7)                          4 (66.7)    16 (64.0)        
  CA125                108             16             92                                    11                 60                                  5          32            
  Over ULN            42 ()         12 (75.0)      30 (32.6)         **0.001**           7 (63.6)           18 (30.0)          **0.043**       5 (100.0)   12 (37.5)   **0.014**
  Normal              66 ()         4 (25.0)       62 (67.4)                             4 (36.4)           42 (70.0)                           0 (0.0)    20 (62.5)        
  ESR                  163             21             142                                   14                 88                                  7          54            
  Over ULN          49 (30.1)       18 (85.7)      31 (21.8)        **\<0.001**          13 (92.9)          20 (22.7)         **\<0.001**      5 (71.4)    11 (20.4)   **0.011**
  Normal            114 (69.9)      3 (14.3)      111 (78.2)                              1 (7.1)           68 (77.3)                          2 (28.6)    43 (79.6)        
  Ferritin             152             21             131                                   16                 84                                  5          47            
  Over ULN          52 (34.2)       14 (66.7)      38 (29.0)         **0.001**           10 (62.5)          24 (28.6)          **0.009**       4 (80.0)    14 (29.8)   **0.043**
  Normal            100 (65.8)      7 (33.3)       93 (71.0)                             6 (37.5)           60 (71.4)                          1 (20.0)    33 (70.2)        
  LDH                  250             25             225                                   18                 145                                 7          80            
  Over ULN          114 (45.6)      14 (56.0)     100 (44.4)           0.271             10 (55.5)          64 (44.1)            0.359         4 (57.1)    36 (45.0)     0.698
  Normal            136 (54.4)      11 (44.0)     125 (55.6)                             8 (45.5)           81 (55.9)                          3 (42.9)    44 (55.0)        
  CK                   149             21             128                                   14                 72                                  7          56            
  Complex            5 (3.4)         1 (4.8)        4 (3.1)            0.537              1 (7.1)           2 (27.8)             0.417          0 (0.0)     2 (3.6)      1.000
  Normal            144 (96.6)      20 (95.2)     124 (96.9)                             13 (92.9)          70 (97.2)                          7 (100.0)   54 (96.4)        
  BM                   150             22             128                                   15                 83                                  7          45            
  Positive          17 (11.3)       4 (18.2)       13 (10.2)           0.279             3 (20.0)            8 (9.6)             0.366         1 (14.3)    5 (11.1)      1.000
  Negative          133 (88.7)      18 (81.8)     115 (89.8)                             12 (80.0)          75 (90.4)                          6 (85.7)    40 (88.9)        

Abbreviations: EBV: Epstein-Barr virus; CRP: serum C reactive protein; ULN: upper limit of normal; β2MG: β2 microglobulin; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; CK: chromosome karyotype; BM: bone marrow.

###### Pathological features of patients in different groups (EBER cut-off: 20%).

  **Variable**    Number.(%)   **All age**   ***P*** **value**   **Elderly group**   ***P*** **value**   **Young group**   ***P*** **value**                         
  -------------- ------------ ------------- ------------------- ------------------- ------------------- ----------------- ------------------- ---------- ----------- -----------
  CD10               250           35               215                                     25                 141                                10         74            
  Positive        60 (24.0)     4 (11.4)         56 (26.0)             0.060             4 (16.0)           35 (24.8)            0.338         0 (0.0)    21 (28.4)     0.060
  Negative        190 (76.0)    31 (88.6)       159 (74.0)                               21 (84.0)         106 (75.2)                          10 (100)   53 (71.6)        
  Bcl6               248           35               223                                     25                 140                                10         73            
  Positive        160 (64.5)    12 (34.3)       148 (66.4)          **\<0.001**          7 (28.0)           91 (65.0)          **0.001**       5 (50.0)   57 (78.1)     0.113
  Negative        88 (35.5)     23 (65.7)        65 (33.6)                               18 (72.0)          49 (35.0)                          5 (50.0)   16 (21.9)        
  MUM1               250           35               215                                     25                 141                                10         74            
  Positive        157 (62.8)    23 (65.7)       134 (62.3)             0.700             16 (64.0)          95 (67.4)            0.741         7 (70.0)   39 (52.7)     0.500
  Negative        93 (37.2)     12 (34.3)        81 (37.7)                               9 (36.0)           46 (32.6)                          3 (30.0)   35 (47.3)        
  GCET1              245           32               213                                     22                 141                                10         72            
  ≥60%            31 (12.7)      3 (9.4)         28 (13.1)             0.776              2 (9.1)           18 (12.8)            1.000         1 (10.0)   10 (13.9)     1.000
  \<60%           214 (87.3)    29 (90.6)       185 (86.9)                               20 (90.9)         123 (87.2)                          9 (90.0)   62 (86.1)        
  FOXP1              230           32               198                                     22                 130                                10         68            
  ≥60%            138 (60.1)    17 (53.1)       121 (61.1)             0.392             10 (45.5)          89 (68.5)          **0.036**       7 (70.0)   32 (47.1)     0.176
  \<60%           92 (35.9)     15 (46.9)        77 (38.9)                               12 (54.5)          41 (31.5)                          3 (30.0)   36 (52.9)        
  LMO2               244           32               222                                     22                 140                                10         72            
  ≥30%            194 (79.5)    25 (78.1)       169 (76.1)             0.439             19 (86.4)         107 (76.4)            0.412         6 (60.0)   62 (86.1)     0.062
  \<30%           50 (20.5)     7 (21.9)         33 (23.9)                               3 (13.6)           33 (23.6)                          4 (40.0)   10 (13.9)        
  CD5                250           35               215                                     25                 141                                10         74            
  Positive         17 (6.8)      2 (5.7)         15 (7.0)              1.000              1 (4.0)            7 (5.0)             1.000         1 (10.0)   8 (10.8)      1.000
  Negative        233 (93.2)    33 (94.3)       200 (93.0)                               24 (96.0)         134 (95.0)                          9 (90.0)   66 (89.2)        
  CD30               250           35               215                                     25                 141                                10         74            
  Positive        25 (10.0)     10 (28.6)        15 (6.5)            **0.001**           7 (28.0)            9 (6.4)           **0.003**       3 (30.0)    6 (6.8)    **0.070**
  Negative        225 (90.0)    25 (71.4)       200 (93.4)                               18 (72.0)         132 (93.6)                          7 (70.0)   68 (93.2)        
  Myc                248           33               215                                     23                 141                                10         74            
  Positive        91 (36.7)     19 (57.6)        72 (33.5)           **0.008**           14 (60.9)          53 (37.6)          **0.035**       5 (50.0)   19 (25.7)     0.140
  Negative        157 (63.3)    14 (42.4)       143 (66.5)                               9 (39.1)           88 (62.4)                          5 (50.0)   55 (74.3)        
  Bcl2               249           35               214                                     25                 140                                10         74            
  Positive        142 (57.0)    14 (40.0)       128 (59.8)           **0.028**           10 (40.0)          87 (62.1)          **0.038**       4 (40.0)   41 (55.4)     0.503
  Negative        107 (43.0)    21 (60.0)        86 (40.2)                               15 (60.0)          53 (37.9)                          6 (60.0)   33 (44.6)        
  DPE             64 (25.6)     15 (42.9)        49 (22.8)           **0.012**           11 (44.0)          35 (24.8)          **0.048**       4 (40.0)   14 (18.9)     0.210
  Others          186 (74.4)    20 (57.1)       166 (77.2)                               14 (56.0)         106 (75.2)                          6 (60.0)   60 (81.1)        
  Ki-67              249           34               215                                     24                 141                                10         74            
  ≥70%            97 (39.0)     23 (67.6)        74 (34.4)          **\<0.001**          17 (70.8)          48 (34.0)          **0.001**       6 (60.0)   26 (35.1)     0.170
  \<70%           152 (61.0)    11 (23.4)       141 (65.6)                               7 (29.2)           93 (66.0)                          4 (40.0)   48 (64.9)        
  MYC-ba             246           32               214                                     23                 140                                9          74            
  Positive        33 (13.4)     10 (31.2)        23 (10.7)           **0.004**           7 (34.4)           15 (10.7)          **0.018**       3 (33.3)   8 (10.8)      0.094
  Negative        213 (86.6)    22 (68.8)       191 (89.3)                               16 (69.6)         125 (89.3)                          6 (66.7)   66 (89.2)        
  BCL2/IGH           247           32               215                                     23                 141                                9          74            
  Positive        32 (13.0)     7 (21.9)         25 (11.6)             0.152             4 (17.4)           19 (13.5)            0.535         3 (33.3)    6 (8.1)      0.054
  Negative        215 (87.0)    25 (78.1)       190 (88.4)                               19 (82.6)         122 (86.5)                          6 (66.7)   68 (91.9)        
  DHL              6 (2.4)      4 (12.1)          2 (1.0)            **0.003**           3 (13.0)            1 (1.0)           **0.009**       1 (10.0)    1 (1.4)      0.225
  Non-DHL         242 (97.6)    29 (87.9)       213 (99.0)                               20 (87.0)         140 (99.0)                          9 (90.0)   73 (98.6)        
  Hans               250           35               215                                     25                 141                                10         74            
  GCB             98 (39.2)     14 (40.0)        84 (39.1)             0.917             9 (36.0)           49 (34.8)            0.904         5 (50.0)   35 (47.3)     1.000
  Non-GCB         152 (60.8)    21 (60.0)       131 (60.9)                               16 (64.0)          92 (65.2)                          5 (50.0)   39 (52.7)        
  Choi               244           23               221                                     22                 140                                10         72            
  GCB             110 (45.1)    10 (43.5)       100 (45.2)             0.092             6 (27.3)           59 (42.1)            0.186         4 (40.0)   41 (56.9)     0.335
  Non-GCB         134 (54.9)    22 (56.5)       112 (54.8)                               16 (72.7)          81 (57.9)                          6 (60.0)   31 (43.1)        
  Tally              246           32               214                                     22                 141                                10         73            
  GCB             68 (27.6)     11 (34.4)        57 (26.6)             0.361             7 (31.8)           35 (24.8)            0.485         4 (40.0)   22 (30.1)     0.717
  Non-GCB         178 (72.4)    21 (65.6)       157 (73.4)                               15 (68.2)         106 (75.2)                          6 (60.0)   51 (69.9)        
  Visco-Young        246           34               212                                     24                 140                                10         72            
  GCB             106 (43.1)    11 (32.4)        95 (44.8)             0.173             6 (25.0)           57 (40.7)            0.144         5 (50.0)   38 (52.8)     1.000
  Non-GCB         140 (56.9)    23 (67.6)       117 (55.2)                               18 (75.0)          83 (59.3)                          5 (50.0)   34 (47.2)        

Abbreviations: EBV: Epstein-Barr virus; DPE: double protein expression; ba: break apart; DHL: double hit lymphoma; GCB:germinal center B cell.

###### Pathological features of patients in different groups (EBER cut-off: 50%).

  Variable       Number.(%)   **All age**   ***P*** **value**   **Elderly group**   ***P*** **value**   **Young group**   ***P*** **value**                          
  ------------- ------------ ------------- ------------------- ------------------- ------------------- ----------------- ------------------- ----------- ----------- -----------
  CD10              250           26               224                                     19                 147                                 7          77            
  Positive       60 (24.0)     3 (11.5)         57 (25.4)             0.116             3 (18.6)           36 (24.5)            0.568          0 (0.0)    21 (27.3)     0.184
  Negative       190 (76.0)    23 (88.5)       167 (74.6)                               16 (81.2)         111 (75.5)                          7 (100.0)   56 (72.7)        
  Bcl6              248           26               222                                     19                 146                                 7          76            
  Positive       160 (64.5)    6 (23.1)        154 (69.4)          **\<0.001**          4 (21.1)           94 (64.4)         **\<0.001**      2 (28.6)    60 (78.9)   **0.010**
  Negative       88 (35.5)     20 (76.9)        68 (30.6)                               15 (78.9)          52 (35.6)                          5 (71.4)    16 (21.1)        
  MUM1              250           26               224                                     19                 147                                 7          77            
  Positive       157 (62.8)    15 (57.7)       142 (63.4)             0.569             11 (57.9)         100 (68.0)            0.377         4 (57.1)    42 (54.5)     1.000
  Negative       93 (37.2)     11 (42.3)        82 (36.6)                               8 (42.1)           47 (32.0)                          3 (42.9)    35 (45.5)        
  GCET1             245           23               222                                     16                 147                                 7          75            
  ≥60%           31 (12.7)      1 (4.3)         30 (13.5)             0.326              0 (0.0)           20 (13.6)            0.223         1 (14.3)    10 (13.3)     1.000
  \<60%          214 (87.3)    22 (95.7)       192 (86.5)                              16 (100.0)         127 (86.4)                          6 (85.7)    65 (86.7)        
  FOXP1             230           23               207                                     16                 136                                 7          71            
  ≥60%           138 (60.1)    10 (43.5)       128 (61.8)             0.088             6 (37.5)           93 (68.4)          **0.014**       4 (57.1)    35 (49.3)     1.000
  \<60%          92 (35.9)     13 (56.5)        79 (38.2)                               10 (62.5)          43 (31.6)                          3 (42.9)    36 (50.7)        
  LMO2              244           23               221                                     16                 146                                 7          75            
  ≥30%           194 (79.5)    17 (73.9)       177 (80.1)             0.586             14 (87.5)         112 (76.7)            0.527         3 (42.9)    65 (86.7)   **0.014**
  \<30%          50 (20.5)     6 (26.1)         44 (19.9)                               2 (12.5)           34 (26.3)                          4 (57.1)    10 (13.3)        
  CD5               250           26               224                                     19                 147                                 7          77            
  Positive        17 (6.8)      2 (7.7)         15 (6.7)              1.000              1 (5.3)            7 (4.8)             1.000         1 (14.3)    8 (10.4)      1.000
  Negative       233 (93.2)    24 (92.3)       209 (93.3)                               18 (94.7)         140 (95.2)                          6 (85.7)    69 (89.6)        
  CD30              250           26               224                                     19                 147                                 7          77            
  Positive        25 (10%)     10 (38.5)        15 (6.7)           **\<0.001**          7 (36.8)            9 (6.1)          **\<0.001**      3 (42.9)     6 (7.8)    **0.024**
  Negative       225 (90.0)    16 (61.5)       209 (93.3)                               12 (63.2)         138 (93.9)                          4 (57.1)    71 (92.2)        
  Myc               248           24               224                                     17                 147                                 7          77            
  Positive       91 (36.7)     12 (50.0)        79 (35.3)             0.155             9 (52.9)           58 (39.5)            0.284         3 (42.9)    21 (27.3)     0.402
  Negative       157 (63.3)    12 (50.0)       145 (64.7)                               8 (47.1)           89 (60.5)                          4 (57.1)    56 (72.7)        
  Bcl2              249           26               223                                     19                 146                                 7          77            
  Positive       142 (57.0)    8 (30.8)        134 (60.1)           **0.004**           6 (31.6)           91 (62.3)          **0.010**       2 (28.6)    43 (55.8)     0.242
  Negative       107 (43.0)    18 (69.2)        89 (39.9)                               13 (8.4)           55 (37.7)                          5 (71.4)    34 (44.2)        
  DPE            64 (25.6)     8 (30.8)         56 (25.0)             0.523             6 (31.6)           40 (27.2)            0.689         2 (28.6)    16 (20.8)     0.639
  Others         186 (74.4)    18 (69.2)       168 (75.0)                               13 (68.4)         107 (72.8)                          5 (71.4)    61 (79.2)        
  Ki-67             249           25               224                                     18                 147                                 7          77            
  ≥70%           97 (39.0)     17 (68.0)        80 (35.7)          **\<0.001**          12 (66.7)          53 (36.1)          **0.001**       5 (71.4)    27 (35.1)     0.100
  \<70%          152 (61.0)    8 (32.0)        144 (64.3)                               6 (33.3)           94 (63.9)                          2 (28.6)    50 (64.9)        
  MYC-ba            246           23               223                                     17                 146                                 6          77            
  Positive       33 (13.4)     6 (26.1)         27 (12.1)             0.099             4 (23.5)           18 (12.3)            0.252         2 (33.3)    9 (11.7)      0.178
  Negative       213 (86.6)    17 (73.9)       196 (87.9)                               13 (76.5)         128 (87.7)                          4 (66.7)    68 (88.3)        
  BCL2/IGH          247           23               224                                     17                 146                                 6          77            
  Positive       32 (13.0)     6 (26.1)         26 (11.6)             0.170             3 (17.6)           20 (13.7)            0.711         3 (50.0)     6 (7.8)    **0.015**
  Negative       215 (87.0)    17 (73.9)       198 (88.4)                               14 (82.4)         127 (86.3)                          3 (50.0)    71 (92.2)        
  DHL             6 (2.4)      3 (12.5)          3 (1.3)            **0.013**           2 (11.8)            2 (1.4)             0.054         1 (14.3)     1 (1.3)      0.161
  Non-DHL        242 (97.6)    21 (87.5)       221 (98.7)                               15 (88.2)         145 (98.6)                          6 (85.7)    76 (98.7)        
  Hans              250           26               224                                     19                 147                                 7          77            
  GCB            98 (39.2)     10 (38.5)        88 (39.3)             0.139             8 (42.1)           50 (34.0)            0.486         2 (28.6)    38 (49.4)     0.437
  Non-GCB        152 (60.8)    16 (61.5)       136 (60.7)                               11 (57.9)          97 (66.0)                          5 (71.4)    39 (50.6)        
  Choi              244           23               221                                     16                 146                                 7          75            
  GCB            110 (45.1)    6 (26.1)        104 (47.1)             0.054             5 (31.2)           60 (41.1)            0.446         1 (14.3)    44 (58.6)   **0.042**
  Non-GCB        134 (54.9)    17 (73.9)       117 (52.9)                               11 (68.8)          86 (58.9)                          6 (85.7)    31 (41.3)        
  Tally             246           23               223                                     16                 147                                 7          76            
  GCB            68 (27.6)     7 (30.4)         61 (27.4)             0.422             6 (37.5)           36 (24.5)            0.105         1 (14.3)    25 (32.9)     0.425
  Non-GCB        178 (72.4)    16 (69.6)       162 (72.6)                               10 (62.5)         111 (75.5)                          6 (85.7)    51 (67.1)        
  Visco-Young       246           25               221                                     18                 146                                 7          75            
  GCB            106 (43.1)    7 (28.0)         99 (44.8)             0.108             5 (27.8)           58 (39.7)            0.325         2 (28.6)    41 (54.7)     0.249
  Non-GCB        140 (56.9)    18 (72.0)       122 (55.2)                               13 (72.2)          88 (60.3)                          5 (71.4)    34 (45.3)        

Abbreviations: EBV: Epstein-Barr virus; DPE: double protein expression; ba: break apart; DHL: double hit lymphoma; GCB:germinal center B cell.
